

New Pathologic Insights into Vulnerable Plaque

TCT Asia Pacific 2007

Renu Virmani, MD

CVPath Institute Inc., 19 Firstfield Road,
Gaithersburg,
Maryland, USA

Conflict of Interest Statement

Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.

Physician Name: Renu Virmani, M.D.

Company/Relationship: Research Grants

Medtronic AVE; Guidant; Abbott; GE Healthcare; Takeda; Atrium Medical Corp.; ev3; Conor Medsystems; TopSpin Medical (Israel) Ltd.; Paracor Medical, Inc.; OrbusNeich; Terumo Corp.; Vascular Therapies, LLC; CardioKinetix; Osiris Therapeutics, Inc.; Edwards Life Sciences; Biomerix; Nitinol Device and Components; Sorin Biomedica Cardio S.r.l; 3F Therapeutics; Hancock Jaffee Labs, Inc.; Cardiovascular Device Design; Coaptus; Biotegra; Cardica, Inc.; Cordis Corp.; Cryo Vascular Systems, Inc.; CVRx, Inc.; diaDexus, Inc.; InfraReDx, Inc.; Kensey Nash Corp.; Medeikon Corp.; MedNova USA, Inc.; Microvention, Inc.; Oregon Medical Laser Center; Spectranetics Corp.; Takeda Pharmaceuticals North America; Toray Industries, Inc.; Vascular Concepts; Volcano Therapeutics, Inc.; BioSensors International; Alchimer S.A. and Relisys.

Consultant: Medtronic AVE; Guidant; W.L. Gore; CryoVascular Systems, Inc.; Volcano Therapeutics Inc.; Precient Medical; Medeikon; CardioMind, Inc.; Direct Flow; and Atrium Medical Corp.

Employment 25%: Cardiovascular Research Foundation


Do not own any stock in any company.

Natural History of Atherosclerosis


- Systemic factors - hyperlipidemia, diabetes mellitus, smoking, hypertension, age and sex, hsCRP, Lp-PLA₂, etc.
- Local factors: at branch points, e.g., carotid bifurcation, abdominal aorta just above bifurcation and coronary branch points, arch vessels at take off, are the sites of atherosclerosis manifestation
- Thrombosis occurs in the coronary arteries at focal points and is most often seen in the proximal segments of the three main coronary arteries (systemic coagulation factors play a role), and occur at sites where there are underlying plaque characteristic to precipitate thrombosis

Branch points are the sites of atherosclerosis and occur in areas of low shear

Carotid Artery




A



B

Left Coronary artery



C






Lesions with Thrombi

- *Plaque Rupture*
- *Plaque Erosion*
- *Calcified Nodule*






Causes of Coronary Thrombosis

Erosion

Rupture




Calcified nodule




Development of Human Coronary Atherosclerosis


Intimal thickening




Intimal xanthoma









Pathologic intimal thickening



Fibrous cap atheroma



Thin-cap Fibroatheroma



- Smooth muscle cells
- Macrophage foam cells
- Extracellular lipid
- Cholesterol clefts
- Necrotic core

- Calcified plaque
- Hemorrhage
- Thrombus
- Healed thrombus
- Collagen

FC = fibrous cap
 LP = lipid pool
 NC = necrotic core

Thin-Cap Atheroma (Vulnerable Plaque) Components

- Necrotic core
- Thin fibrous cap (< 65 μm)
- Cap infiltrated by macrophages and lymphocytes
- Cap composition – type 1 collagen and few smooth muscle cells

A Non-Hemodynamically Limiting Thin-cap Fibroatheroma





Fig 2-2


Morphologic Characteristics of Plaque Rupture and Thin-cap Fibroatheromas

Plaque type	Necrotic Core (%)	Fibrous cap Thickness (μm)	M Φ s (%)	SMCs (%)	T-lymph	Calcification Score
Rupture	34 \pm 17	23 \pm 19	26 \pm 20	0.002 \pm 0.004	4.9 \pm 4.3	1.53 \pm 1.03
Thin-cap Fibroatheroma	23 \pm 17	<65 μm	14 \pm 10	6.6 \pm 10.4	6.6 \pm 10.4	0.97 \pm 1.1
P value	0.01		0.005	ns	ns	0.014

Mean values are represented \pm standard deviation. Abbreviations: M Φ s= macrophages, SMCs= smooth muscle cells, T-lymph= T-lymphocytes

Relationship of Fibrous Cap Thickness to Macrophage Infiltration





Type II DM



Type I DM

Non-Diabetic



MACs

T cells

HLA-DR



Remodeling in Varying Coronary Lesion Morphologies



Predictors Remodeling Score*

Independent of Age, Sex, and Distance from Ostium

Plaque Parameters	T	P
% Macrophages	5.3	<0.0001
Fibrous calcium	4.5	<0.0001
% Lipid Core	4.3	<0.0001
% Fibrous tissue	-3.8	<0.0001
% Calcified lipid core	3.0	0.002
Medial atrophy	2.0	0.05
Adventitial thickness	-1.6	0.11

*IEL area – expected IEL area/plaque area

Inflammation plays a primary role in progression of human atheroma

- ❑ Key role of inflammation in atherosclerosis is evident in many epidemiology studies indicating an association between inflammatory markers: CRP, interleukin-6, oxLDL and risk of cardiovascular events.
- ❑ Lp-PLA₂ is a novel inflammatory marker that has been the recent focus of several epidemiology studies showing that plasma levels predict cardiovascular events
- ❑ Lp-PLA₂ mRNA and protein have been detected in macrophages in man and rabbit non-coronary atherosclerotic lesions

Lp-PLA₂

- Lipoprotein-associated phospholipase A₂(Lp-PLA₂), an enzyme bound mainly to LDL-cholesterol, results in the formation of pro-inflammatory lysophosphatidylcholine and oxidized fatty acids
- Lp-PLA₂ induces cell death of human monocytes/macrophages in the presence of mildly oxidized LDL (*Curr Opin Lipidol* 2005;16:442-446)
- Hydrolysis of platelet activating factor and other phospholipids by Lp-PLA₂ may however reduce inflammation
- The pro- or anti-inflammatory role of Lp-PLA₂ in humans coronary atherosclerosis has not been established

Morphometric assessment of vessel area, stenosis, necrotic core size, and macrophage density from 25 pts with SCD (frozen sections)


Plaque Type	IEL mm ²	Stenosis %	Necrotic core %	Macrophage (%CD68)
Pathologic intimal thickening (n=7)	10.4±2.5	45.8±18.8	0	3.1±3.2
Fibroatheroma (n=8)	10.0±4.4	70.8±14.7	14.5±8.6	7.4±5.4
Thin-cap Fibroatheroma(n=8)	9.0±1.7	82.4±8.8	32.1±18.3	8.2±4.1
Plaque rupture (n=7)	13.2±6.4	84.6±7.5	36.5±14.0	11.4±3.7
P value	ns	<0.0001*	<0.0001**	<0.01***

Lipoprotein-associated phospholipase A₂ (Lp-PLA₂), apoptosis by cell type, and cell density in macrophages and SMC rich regions


Plaque Type	Lp-PLA ₂	Apoptosis~		Cell Density(cells/mm ²)	
		Macrophages	SMC's	Macrophages	SMC's
PIT (n=7)	0.4±0.5	45.8±18.8	0	1005±374	
FA (n=8)	2.5±2.6	70.8±14.7	14.5±8.6	858±286	
				1247±493	
TCFA(n=8)	11.8±5.4	82.4±8.8	32.1±18.3	1661±495	
				1183±257	
PR(n=7)	22.9±13.8	84.6±7.5	36.5±14.0	1796±430	
				1074±355	
P value	0.0001*	<0.0001*	<.0001**	0.03**	ns

* Significant differences between rupture vs. thin cap fibroatheroma, fibroatheroma, and pathologic intimal thickening. ** significant difference between rupture and pathologic intimal thickening. ~Apoptosis and cell density measurements were done in the same region.


Pathologic Intimal thickening





Fibroatheroma



Thin Cap Fibroatheroma




Plaque Rupture











E.

% Lp-PLA₂ Staining in Varying Coronary Plaque Morphologies

* significant differences between



Macrophage Apoptosis in Various Human Coronary Plaque Morphologies




Lipoprotein-Associated A₂ Protein Expression in natural progression of Human Coronary Atherosclerosis


Summary:

- ❑ First study to characterize the expression of Lp-PLA₂ protein within human coronary atheroma of various morphologies or phenotypes.
- ❑ Lp-PLA₂ was expressed by macrophages within fibrous cap region of rupture-prone and ruptured lesions.
- ❑ Lp-PLA₂ staining co-localized with apoptotic macrophages
- ❑ Lp-PLA₂ staining was also intense in regions abundant in lipids and oxidative products (e.g., necrotic core)
- ❑ Lp-PLA₂ and its enzymatic products may play a role in promoting plaque instability.

Plaque Development and Expression of OxLDL-E06







PIT - pathologic intimal thickening
 Early FA - early fibroatheroma
 Late FA - late fibroatheroma
 TCFA - thin-cap fibroatheroma




Thin-cap Fibroatheroma

Recent Intraplaque Hemorrhage is seen at Multiple sites in Patients Dying SCD







Plaque Hemorrhage



Phase Separation of Erythrocyte-Derived Cholesterol in Coronary and Non-Coronary Diseases

Thin Fibrous Cap Atheroma



Hemorrhagic Pericarditis



Hemorrhage
Periphery




Hemorrhage
Core



Plaque Types Studied


A.

Pathologic Intima Thickening




B.

Fibroatheroma 'Early' Core




C.

Fibroatheroma 'Late' Core



D.

Thin Cap Fibroatheroma



Morphometric Analysis of Hemorrhagic Events in Human Coronary Plaques from Sudden Death Victims

Plaque Type	GpA Score	Iron	Necrotic Core (mm ²)	MΦ (mm ²)
PIT no core (n=129)	0.09±0.04	0.07±0.05	0.0	0.002±0.001
FA early core (n=79)	0.23±0.07	0.17±0.08	0.06±0.02	0.018±0.004
FA late core (n=105)	*0.94±0.11	*0.41±0.09	*0.84±0.08	*0.059±0.007
TCFA (n=52)	*1.60±0.20	*1.24±0.24	*1.95±0.30	*0.142±0.016

Values are reported as the means±SE, *p<0.001 versus early core. The number in parenthesis represent the number of lesions examined;the total number= 365. MΦ = macrophages


Plaque hemorrhage contributes to enlargement of the necrotic core

- Importance has been shown in human plaques - red cell membrane contributes to free cholesterol and larger necrotic cores.
- Macrophage accumulation is triggered by crystallization of cholesterol from erythrocyte membrane and foreign body reaction as seen in cholesterol granulomas and e.g., receptors on erythrocytes bind a wide array of chemokines, MCP-1; lipid oxidation from senescent RBCs or iron-catalyzed reactions may liberate potent chemoattractants

Plaque Vasa Vasorum

- Plaque capillaries are observed in atherosclerotic plaques with plaque thickness > 0.5 mm, suggesting that wall ischemia may be a determinant of neovascularization.
- Heistead and Armstrong reported a 5 fold increase in intimal/medial blood flow from proliferating micro vessels in monkeys fed a high cholesterol diet for 17 months. (Arteriosclerosis 1986)
- Plaque Vv may be a potential source of inflammation within the plaque [expression of VCAM-1, ICAM-1 and E-selectin has been shown in plaque Vv (O'Brian, et al. AJP 1994)].
- Inflammation and matrix composition of atherosclerotic plaques may also influence angiogenesis.

Adventitial Vasa Vasorum Heterogeneity among different vascular beds




Low vasa vasorum density in internal thoracic artery may be responsible for the low incidence of atherosclerosis

Gallili et al. J Vasc Surg 2004;40:529 and J Thorac Cardiovasc Surg 2005;129:767


Intraplaque Vasa Vasorum in Coronary Plaques with a Necrotic Core

150 μm thick sections stained with Ulex

A





B




Vasa Vasorum by Plaque Type

K Mean No. of Vasa Vasorum by Plaque Type


Thin-Cap Fibroatheroma



Plaque Rupture



Stable Plaque



Conclusions

- ❑ Plaques occur focally at branch points in the presence of systemic risk factors
- ❑ The morphologic characteristics most predictive for the presence of unstable vs. stable plaque is necrotic core size, plaque area and extent of macrophage infiltration in the fibrous cap.
- ❑ Intra plaque hemorrhage is responsible for enlargement of necrotic core, macrophage infiltration and progressive luminal narrowing
- ❑ Non invasive detection of vulnerable plaques is the only mechanism through which morbidity and mortality for CAD can be reduced or eliminated.